Hikma Weighs Unsolicited Approaches for Injectable-Drug Unit

Hikma Pharmaceuticals Plc said it’s considering a possible sale of its injectable-medicines business, the second-biggest by volume in the U.S., after receiving unsolicited expressions of interest.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.